Prostate Cancer PDX (MSK / MD Anderson, 2023)

Overview

Multi-platform integrative genomic characterization of 44 patient-derived xenograft (PDX) models from 38 prostate cancer patients, including adenocarcinoma and neuroendocrine prostate cancer (NEPC) variants. Samples from primary sites and metastases; both therapy-naive and castration-resistant. Data deposited in cBioPortal as prad_msk_mdanderson_2023 and dbGaP (phs003420.v1.p1). Cross-referenced with prad_tcga and prad_su2c_2019. PMID:38488813

Composition

  • 44 PDX models derived from 38 patients with PRAD, including adenocarcinoma, PRNE, poorly differentiated carcinomas, and sarcomatoid carcinomas. PMID:38488813
  • Samples from primary sites and metastases (bone, lymph node, circulating tumor cells). PMID:38488813

Assays / panels (linked)

Papers using this cohort

  • PMID:38488813 — Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.

Notable findings derived from this cohort

  • 91% of PDXs carried oncogenic alterations in at least one of AR, RB1, TP53, or PTEN. PMID:38488813
  • TMPRSS2-ERG fusion in 13 PDX models; TMPRSS2-ETV4 fusion in 2 PDXs. PMID:38488813
  • CDK12 alterations identified in 4 PDXs via multi-platform integration; biallelic mutations and structural/splicing-mediated inactivation would have been missed without integrative analysis. PMID:38488813
  • RB1 alterations significantly more frequent in NEPC than adenocarcinoma (P=0.0002); RB1 and AR expression significantly lower in NEPC. PMID:38488813
  • FGFR1 expression inversely correlated with promoter CpG methylation in PDXs and prad_tcga; three downstream genes preferentially expressed in bone metastases in prad_su2c_2019. PMID:38488813

Sources

This page was processed by entity-page-writer on 2026-04-11.